Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy
Authors:
Open Access
- 15 August 2013
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 123 (9) , 3997-4009
Abstract
Many oncology drugs are administered at their maximally tolerated dose without the knowledge of their optimal efficacious dose range. In this study, we describe a multifaceted approach that integrated preclinical and clinical data to identify the optimal dose for an antiangiogenesis agent, anti-EGFL7. EGFL7 is an extracellular matrix–associated protein expressed in activated endothelium. Recombinant EGFL7 protein supported EC adhesion and protected ECs from stress-induced apoptosis. Anti-EGFL7 antibodies inhibited both of these key processes and augmented anti-VEGF–mediated vascular damage in various murine tumor models. In a genetically engineered mouse model of advanced non–small cell lung cancer, we found that anti-EGFL7 enhanced both the progression-free and overall survival benefits derived from anti-VEGF therapy in a dose-dependent manner. In addition, we identified a circulating progenitor cell type that was regulated by EGFL7 and evaluated the response of these cells to anti-EGFL7 treatment in both tumor-bearing mice and cancer patients from a phase I clinical trial. Importantly, these preclinical efficacy and clinical biomarker results enabled rational selection of the anti-EGFL7 dose currently being tested in phase II clinical trials.Keywords
This publication has 35 references indexed in Scilit:
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic responseNature, 2012
- Antiangiogenic therapy—evolving view based on clinical trial resultsNature Reviews Clinical Oncology, 2012
- Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7Blood, 2010
- Expression and clinical significance of EGFL7 in malignant gliomaJournal of Cancer Research and Clinical Oncology, 2010
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)Journal of Clinical Oncology, 2008
- Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progressionProceedings of the National Academy of Sciences, 2008
- Epidermal growth factor-like domain 7 protects endothelial cells from hyperoxia-induced cell deathAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008
- The biology of VEGF and its receptorsNature Medicine, 2003
- A phase I study of paclitaxel for mobilization of peripheral blood progenitor cellsBone Marrow Transplantation, 1999
- On the Interpretation of χ 2 from Contingency Tables, and the Calculation of PJournal of the Royal Statistical Society, 1922